mAb and ADC Offerings
The Risk of Nitrosamine Impurities in Biologics: What Biopharma Developers Need to Know
New Nitrosamine Guidance
Advancing Peptide Therapeutics: Challenges and Opportunities in a Booming Market
Understanding and Implementing USP <665> for Single-Use Systems
The High-Stakes Nature of Nitrosamine Impurities in APIs
Deep CMC testing expertise across
the pharmaceutical spectrum
One partner for your entire
drug development journey
Let’s advance your development project
175
+
PhD-level scientists
800
+
team members in Europe & U.S.
700
+
customers worldwide
19
of the top 20 pharma companies choose Solvias
